Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.69 |
| ▸ | PTAFR | P25105 | 1/20 | 0.69 |
| ▸ | HTR1D | P28221 | 1/20 | 0.69 |
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.52 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | PRKCG | P05129 | 1/20 | 0.50 |
| ▸ | PRKCB | P05771 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | PRKCH | P24723 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243890 | 1.00 | ADRA1D (0.69) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL878627 | 0.87 | SMN1; SMN2 (0.53) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL5720514 | 0.87 | SMN1; SMN2 (0.65) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL30652570 | 0.86 | ADRA1D (0.78) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL15263707 | 0.85 | ADRA1D (0.78) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL8874191 | 0.85 | MAPK1 (0.54) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL19821628 | 0.83 | MAPT (0.71) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL30278565 | 0.83 | MAPT (0.71) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL6619229 | 0.82 | ADRA1D (0.98) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL4804148 | 0.82 | SMN1; SMN2 (0.64) | ADRA1DPTAFRHTR1DHTR2CADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229157-A1 | COMPRESSED CHEWING GUM TABLET | Fertin Pharma A/S (DK) | 2010-09-22 | — | — | EP | claimed |
| EP-2229156-A1 | CHEWING GUM TABLET AND METHOD OF DOSING PHARMACEUTICALLY ACTIVE INGREDIENTS IN SUCH CHEWING GUM TABLET | Fertin Pharma A/S (DK) | 2010-09-22 | — | — | EP | claimed |
| EP-2229158-A1 | COMPRESSED CHEWING GUM TABLET | Fertin Pharma A/S (DK) | 2010-09-22 | — | — | EP | claimed |
| WO-2009080022-A1 | COMPRESSED CHEWING GUM TABLET | FERTIN PHARMA A/S (DK) | 2009-07-02 | — | — | WO | claimed |
| WO-2009080020-A1 | CHEWING GUM TABLET AND METHOD OF DOSING PHARMACEUTICALLY ACTIVE INGREDIENTS IN SUCH CHEWING GUM TABLET | FERTIN PHARMA A/S (DK) | 2009-07-02 | — | — | WO | claimed |
| WO-2009080021-A1 | COMPRESSED CHEWING GUM TABLET | FERTIN PHARMA A/S (DK) | 2009-07-02 | — | — | WO | claimed |
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-04-05 | — | — | US | claimed |
| US-20240238240-A1 | Cannabinoid Pouch | NORDICCAN A/S (DK) | 2024-07-18 | — | — | US | disclosed |
| US-11963944-B2 | Cannabinoid pouch | NORDICCAN A/S (DK) | 2024-04-23 | — | — | US | disclosed |
| WO-2024077085-A1 | TARGETING PHOSPHOLIPASE A2 (PLA2) IN CANCER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11911375-B2 | Solid oral nicotine formulation | FERTIN PHARMA A/S (DK) | 2024-02-27 | — | — | US | disclosed |
| US-11534421-B2 | Cannabinoid pouch | NORDICCAN A/S | 2022-12-27 | — | — | US | disclosed |
| EP-4000424-B1 | NICOTINE POUCH COMPOSITION | PHILIP MORRIS PRODUCTS SA (CH) | 2022-11-09 | — | — | EP | disclosed |
| EP-0948605-A1 | TRUNCATED PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE | ICOS CORPORATION (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0523189-B1 | CATIONIC LIPIDS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | VICAL INC (US) | 1999-06-16 | — | — | EP | disclosed |
| WO-1999009147-A1 | TRUNCATED PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE | ICOS CORPORATION (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1997040838-A1 | NEW USE | SCOTIA LIPIDTEKNIK AB (SE) | 1997-11-06 | — | — | WO | disclosed |
| WO-1997031660-A1 | CONTACT LENS TREATING COMPOSITIONS, METHODS OF TREATMENT, AND NOVEL LENSES | VISION PHARMACEUTICALS L.P. (US) | 1997-09-04 | — | — | WO | disclosed |
| EP-0673426-A1 | PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE | ICOS CORPORATION (US) | 1995-09-27 | — | — | EP | disclosed |
| WO-1995009921-A1 | PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE | ICOS CORPORATION (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | PGF, PLAT, PTAFR | ADRA1D 1551/4885PTAFR 3/4885HTR1D 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.